Notes in Testis

To Subscribe, use this Key

Status	Last Update	Fields
Published	02/18/2024	GU \| Testicle \| Pure seminoma \| Stage II \| RT Planning
Published	02/18/2024	Germ cell tumour \| Surgery (lecture part II day 9/2020)
Published	02/18/2024	MRS \| Testis \| 1.3 \| Pathology \| Benign lesions
Published	02/18/2024	MRS \| Testis \| 1.4 \| Classification
Published	02/18/2024	MRS \| Testis \| 1.2.3 \| Germ cell tumours \| Precursor lesion and pathogenesis
Published	02/18/2024	MRS \| Testis \| 1.1 \| Anatomy
Published	02/18/2024	MRS \| Testis \| 1.2.1 \| Epidemiology (testicular GCT)
Published	02/18/2024	MRS \| Testis \| 1.2.2 \| Aetiology / Risk factors
Published	02/18/2024	MRS \| Testis \| 1.5.1 \| Seminoma \| Classical seminoma
Published	02/18/2024	MRS \| Testis \| 1.5.2 \| Seminoma \| Spermatocytic seminoma
Published	02/18/2024	MRS \| Testis \| 1.6.1 \| NSGCT \| Embryonal carcinoma
Published	02/18/2024	MRS \| Testis \| 1.6.2 \| NSGCT \| Yolk sac tumour
Published	02/18/2024	MRS \| Testis \| 1.6.3 \| NSGCT \| Choriocarcinoma
Published	02/18/2024	MRS \| Testis \| 1.6.4 \| NSGCT \| Teratoma
Published	02/18/2024	MRS \| Testis \| 1.6.5 \| NSGCT \| Mixed GCT
Published	02/18/2024	MRS \| Testis \| 1.7 \| GCT \| Summary table - seminoma, spermatocytic seminoma, embryonal carcinoma, yolk sac tumour, choriocarcinoma, teratoma, lymphoma
Published	02/18/2024	MRS \| Testis \| 1.8.1 \| Sex cord stromal \| Leydig cell tumours (1-3%)
Published	02/18/2024	MRS \| Testis \| 1.8.2 \| Sex cord stromal \| Sertoli cell tumours (<1%)
Published	02/18/2024	MRS \| Testis \| 1.8.3 \| Sex cord stromal \| Granulosa cell tumour
Published	02/18/2024	MRS \| Testis \| 1.9.1 \| Precursor lesions \| Intratubular germ cell neoplasia
Published	02/18/2024	MRS \| Testis \| 2.1 \| Clinical presentation  and biologic behaviour
Published	02/18/2024	MRS \| Testis \| 2.2 \| Workup
Published	02/18/2024	MRS \| Testis \| 2.3 \| Serum tumour markers
Published	02/18/2024	MRS \| Testis \| 2.4 \| Differential diagnosis
Published	02/18/2024	MRS \| Testis \| 2.5 \| Staging
Published	02/18/2024	MRS \| Testis \| 2.6 \| Prognostic classification
Published	02/18/2024	MRS \| Testis \| 3.1 \| Management overview
Published	02/18/2024	MRS \| Testis \| 3.2 \| GCT \| General management principles
Published	02/18/2024	MRS \| Testis \| 4.1.1 \| Seminoma \| Stage IA/B \| Surgery
Published	02/18/2024	MRS \| Testis \| 4.1.3 \| Seminoma \| Stage IA/B \| Postop Mx \| Radiotherapy
Published	02/18/2024	MRS \| Testis \| 4.1.4 \| Seminoma \| Stage IA/B \| Postop Mx \| Chemotherapy
Published	02/18/2024	MRS \| Testis \| 4.2 \| Seminoma \| Stage II A/B
Published	02/18/2024	MRS \| Testis \| 4.3 \| Seminoma \| Stage IIC-III
Published	02/18/2024	MRS \| Testis \| 4.4 \| Seminoma \| Relapse after RT
Published	02/18/2024	MRS \| Testis \| 4.5 \| Seminoma \| Scrotal violation
Published	02/18/2024	MRS \| Testis \| 5.1 \| NSGCT \| Risk stratification
Published	02/18/2024	MRS \| Testis \| 5.2.1 \| NSGCT \| Stage IA/B, Low risk
Published	02/18/2024	MRS \| Testis \| 5.2.2 \| NSGCT \| Stage IA/B, high risk
Published	02/18/2024	MRS \| Testis \| 5.2.3 \| NSGCT \| Stage IS ("Good risk")
Published	02/18/2024	MRS \| Testis \| 5.2.4 \| NSGCT \| Stage IIA ("Good risk")
Published	02/18/2024	MRS \| Testis \| 5.2.5 \| NSGCT \| Stage IIB ("Good risk")
Published	02/18/2024	MRS \| Testis \| 5.2.6 \| NSGCT \| Stage III (Good, intermediate and poor risk)
Published	02/18/2024	MRS \| Testis \| 6 \| Intratubular germ cell neoplasia (ITGCN)
Published	02/18/2024	MRS \| Testis \| 5.3 \| Extragonadal GCTs
Published	02/18/2024	MRS \| Testis \| 7 \| Testicular lymphoma
Published	02/18/2024	MRS \| Testis \| 8 \| Sex-cord stromal tumour (or teratoma in children)
Published	02/18/2024	MRS \| Testis \| 9.1 \| Seminoma \| RT technique
Published	02/18/2024	MRS \| Testis \| 9.2 \| Hemiscrotal RT
Published	02/18/2024	MRS \| Testis \| 9.3 \| Bleomycin
Status	Last Update	Fields